ClinicalTrials.gg
RecruitingNCT06463886Updated Oct 15, 2026

Striving Towards EmPowerment and Medication Adherence R01

An interventional study of STEP-AD and Enhanced treatment as usual (E-TAU) in Hiv and Mental Health Issue, sponsored by University of Miami. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University of Miami · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 15, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a study for Black women living with HIV to test a counseling program for Black women living with HIV. This participant may be a good fit if the participant is a Black woman, living with HIV, has a history of trauma, and is currently taking Antiretroviral Therapy (ART) medicines

02

Conditions studied

  • Hiv
  • Mental Health Issue

Keywords

  • HIV
  • Black women
  • Trauma
  • Stigma
  • Medication adherence
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 250 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Black
  2. Living with
  3. Female
  4. Age 18 or older
  5. English speaking
  6. Viral load non-suppression (>200 ml) within the past year OR a detectable HIV viral load (>/= 20 within the past year) OR a lack of HIV viral load measure for 6 consecutive months or more during the past 12 months OR missed HIV care visits greater than 6 months within the past year
  7. History of trauma/abuse
  8. Capable of completing and fully understanding the process and study procedures

Exclusion criteria

Exclusion criteria:

  1. Unable to completely and fully understand the process and the study procedures
  2. Significantly interfering mental health symptoms (e.g., active psychosis that is untreated)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    STEP-AD

    Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled "Striving Towards EmPowerment and Medication Adherence". Participants will be in this group for a total of up to 1.5 years.

    Behavioral: STEP-AD

  • Active comparator
    Enhanced treatment as usual

    Participants in the comparison condition will also complete 10 in person sessions. The first session will consist of a session on healthy living with HIV. The remaining 9 sessions will consist of neutral (daily events) writing. Participants will be in this group for a total of up to 1.5 years.

    Behavioral: Enhanced treatment as usual (E-TAU)

Interventions

  • BehavioralSTEP-AD

    This in-person STEP-AD intervention will consist of 10 sessions. Session 1: Life Steps Adherence Session 2: Psychoeducation on the treatment model Session 3: Substance Use and Enhancing Resilience Session 4: Trauma Impact Session 5: Cognitive Restructuring Session 6: Impact of Unique Enacted Stressors and Coping Session 7: HIV Stigma Impact and Coping Session 8: Stressors Women Face and Coping Session 9: Body Image and Healthy Relationships Session 10: Practice, Review, and Relapse Prevention. Each session lasts for about 40 to 60 minutes.

  • BehavioralEnhanced treatment as usual (E-TAU)

    Participants assigned to the E-TAU condition will receive 10 in person sessions to ensure comparable contact time with study staff and identical incentives. The first session will consist of a session on healthy living with HIV (CDC content on HIV 101 \[highlights importance of engaging in care, adhering to medication, finding support\], nutrition, and physical activity. The remaining 9 sessions will consist of neutral (daily events) writing. Women will be asked to write a description of their plans for the next 24 hours.

06

What researchers measure

Primary outcomes

  1. Change in viral suppression

    HIV viral load \<200 copies/ml time averaged. Measured by blood specimen.

    Time frame: Baseline up to 1.5 years

Secondary outcomes

  1. Change in antiretroviral (ART) adherence

    A 3-item self-report instrument that will measure reported adherence to ART. Responses range from 1 to 6. Responses will be averaged (min average of 1, max average of 6) across items with higher scores indicating higher adherence to ART medication.

    Time frame: Baseline up to 1.5 years

  2. Change in adherence to anti-retroviral medications questionnaire

    A list of 12 reasons why individuals may miss taking their ART (e.g., forgot, change in routine) will be used from the AIDS Clinical Trials Group. The minimum score is 0 (no endorsed reasons for missing medication) and maximum score is 36 (endorsing more reasons for missing ART medication).

    Time frame: Baseline up to 1.5 years

  3. Change in engagement in HIV care

    Number of kept versus number of scheduled visits verified by self-report.

    Time frame: Baseline up to 1.5 years

  4. Change in PTSD as measured by PCL-5

    Measured by the Posttraumatic Stress Disorder Checklist (PCL)-5, a 20-item self-report measure of PTSD symptoms. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items. Higher scores indicate higher PTSD severity.

    Time frame: Baseline up to 1.5 years

  5. Change in Post-traumatic cognitions measured by PTCI

    The Posttraumatic Cognitions Inventory (PTCI) is a 36-item, self-report questionnaire, and each item is rated on a 7-point Likert scale that ranges from 1 (totally agree) to 7 (totally disagree).

    Time frame: Baseline up to 1.5 years

  6. Change in Post-traumatic Stress Disorder Diagnosis

    A structured mental health diagnostic interview will be administered to evaluate participants' mental health symptoms and whether they meet criteria for mental health diagnoses (e.g. Post-traumatic Stress Disorder).

    Time frame: Baseline up to 1.5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2029, 57 months after the start.

Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 57 months is above that.

Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 18, 2024
StartActual
Aug 19, 2024
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Cis-gender femaleNow Female
  • EditedViral load non-suppression (>200 ml) within the past year orOR a detectable HIV viral load (>/= 20 within the past year) OR a lack of HIV viral load measure for 6 consecutive months or more during the past 12 months OR missed HIV care visits greater than 6 months within the past year
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Cis-gender femaleNow Female
    • EditedViral load non-suppression (>200 ml) within the past year orOR a detectable HIV viral load (>/= 20 within the past year) OR a lack of HIV viral load measure for 6 consecutive months or more during the past 12 months OR missed HIV care visits greater than 6 months within the past year
    + 5 other changes: verification date, responsible party, conditions, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06463886
Responsible party
Sannisha K Dale (Professor, University of Miami) — Principal investigator
First posted
Jun 18, 2024
Start date
Aug 19, 2024
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Sannisha Dale, PhD
Contact
sdale@med.miami.edu
3052841991
Shine Research
Contact
shineresearch@miami.edu
3052436714
Sannisha Dale, PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion